plus

HTX Launches “$1 Margin Trade”: Start Trading with Just 1 USDT, Enjoy Guaranteed First-Loss Coverage, Plus Share $40,000 in Rewards

PANAMA CITY, May 25, 2026 /PRNewswire/ -- For crypto beginners, the steep learning curve is the biggest hurdle to getting started…

2 weeks ago

Marking its 20-year legacy, Star Health launches ‘Value Plus’ affordable health insurance with nearly 20% lower premiums

Star Health marks 20 years of its foundation with health insurance plan offering nearly 20% lower premiums in Non metro…

3 weeks ago

Davido, Alkaline & Wizkid to Headline Afro Plus Fest 2026

Festival Expands to Three Days at Northwest Stadium Complex in Prince George's County, MD — Sept. 4–6[LINK TO ASSETS]LANDOVER, Md.,…

3 weeks ago

GIGABYTE Launches Z890 Plus Series Motherboards Supporting Intel Core Ultra 200S Plus Series Processors and CQDIMM Technology

TAIPEI, March 11, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, introduces the Z890 Plus Series Motherboards engineered to…

3 months ago

Paingone Plus TENS Pen Featured in 2026 Consumer Report Examining FDA Clearance Status, TENS Pain Therapy Research, and Portable Pain Relief Device Verification

Tukwila, WA, March 05, 2026 (GLOBE NEWSWIRE) -- This report examines publicly available marketing statements and published research literature. Where…

3 months ago

Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema

October 28, 2025 16:05 ET  | Source: Tactile Systems Technology, Inc. MINNEAPOLIS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tactile Systems…

7 months ago

DFSK Celebrates 20 Years of Global Expansion with E5 PLUS, the First Overseas New Energy Strategic Model, Rolls Off the Production Line

CHONGQING, China, Oct. 22, 2025 /PRNewswire/ -- On October 22, 2025, at the Chongqing SERES Shuangfu Plant, DFSK's first overseas new…

8 months ago

IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

October 20, 2025 02:30 ET  | Source: IO Biotech Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression…

8 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

October 19, 2025 08:00 ET  | Source: Replimune, Inc. WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc.…

8 months ago